UNSPSC 51122501: Bretylium/dextrose

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV300. This VA Drug Class (CV300) classifies this compound as belonging to the group ANTIARRHYTHMICS.

UNSPSC 51122501 Bretylium/dextrose, a Commodity code, encompasses emergency medications and pharmaceutical products that state and local governments procure for fire rescue services, emergency medical response, and public health programs. The work being solicited under this code involves supplying advanced life support medications, generic multi-source pharmaceuticals, and OTC products through competitive sealed-bid and RFP processes, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act standards, and expiration-date warranties. Issuing bodies include city fire departments, state health and human services agencies, and multistate cooperative purchasing alliances; the Florida and Minnesota jurisdictions show recent activity, with the City of Tampa and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) among active buyers.

Recent activity spans emergency response procurement and statewide cooperative contracting. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, seeking Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with a due date of April 8, 2026 and an estimated contract value of $40,000.00; the solicitation included a 5 percent Small Local Business Enterprise (SLBE) bid discount and required OSHA Safety Data Sheets and WCAG 2.2 Level AA accessibility documentation. MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to work through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with contract awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. Texas Health and Human Services Commission issued exploratory RFI HHS0017013 in April 2026 to assess vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The code shows moderate geographic spread across Florida, Minnesota, Oregon, and Texas.